Skip to content

Find a Doctor

Call To Schedule

847.570.5020

With more than 1900 primary care physicians and specialists, NorthShore University HealthSystem offers a team of experts representing a vast array of specialties, you have a choice of leading medical experts for you to select from for your care.

Katharine A. Yao, M.D.

Katharine A. Yao, M.D.
Log into NorthShoreConnect
Request Appointment
Conditions & Procedures

Conditions

Breast Cancer, Melanoma

Procedures

Axillary Node Dissection, Groin Dissection for Melanoma, Nipple Sparing Mastectomy, Sentinel Node Biopsy, Surgical Oncology in Breast
General Information

Gender

Female

Affiliation

NorthShore Medical Group

Expertise

Breast Surgery

Academic Rank

Clinical Associate Professor

Languages

English

Board Certified

Surgery

Clinical Service

Surgical Oncology
Education, Training & Fellowships

Medical School

South Illinois University School of Medicine, 1994

Residency

McGaw Medical Center of Northwestern University, 2001

Fellowship

John Wayne Cancer Institute, 2003
A

NorthShore Medical Group

2650 Ridge Ave.
Suite 1155
Evanston, IL 60201
847.570.1700 847.733.3695 fax This location is wheelchair accessible.
B

NorthShore Medical Group

2650 Ridge Ave.
Kellogg Cancer Center
Evanston, IL 60201
847.570.1700 847.733.3695 fax This location is wheelchair accessible.

Every effort has been made to ensure the accuracy of the information in this directory. However, some changes may occur between updates. Please check with your provider to ensure that he or she participates in your health plan.

Aetna HMO/PPO/POS
BCBS HMOI
BCBS POS-- Blue Choice
BCBS PPO - BCBS PPO
Beechstreet PPO
CCN PPO
CIGNA Choice Fund
CIGNA Choice Fund PPO
CIGNA EPO
CIGNA Network
CIGNA Network Open Access
CIGNA POS
CIGNA POS Open Access
CIGNA PPO
CIGNA:Open Access Plus
First Health PPO
Galaxy PPO
Great West POS
Great West PPO
Healthcares Finest Network PPO
Humana Choice Care PPO
Humana IPA--HMO
Humana POS
Humana PPO
Medicare Cook County
Medicare Lake County
Multiplan Admar PPO
Multiplan Formost PPO
Multiplan Health Network PPO
Multiplan Wellmark PPO
NorthShore Employee Network
PHCS PPO
Preferred Plan PPO
Railroad Medicare - Cook County
UHC All Commercial Products
Unicare PPO

  • Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients.

    Ann Surg Oncol. 2012 Oct;19(10):3257-63

    Authors: Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J, Stork-Sloots L, Generali D

    Abstract
    PURPOSE: To compare breast cancer subtyping with the three centrally assessed microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    METHODS: BluePrint, MammaPrint, and TargetPrint were all performed on fresh tumor samples. Microarray analysis was performed at Agendia Laboratories, blinded for clinical and pathological data. IHC/FISH assessments were performed according to local practice at each institution; estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) assessments were performed on 132 samples, and Ki-67 on 79 samples.
    RESULTS: The concordance between BluePrint and IHC/FISH subtyping was 94 % for the Luminal-type, 95 % for the HER2-type, and 94 % for the Basal-type subgroups. The concordance of BluePrint with subtyping using mRNA single gene readout (TargetPrint) was 96 % for the Luminal-type, 97 % for the HER2-type, and 98 % for the Basal-type subgroups. The concordance for substratification into Luminal A and B using MammaPrint and Ki-67 was 68 %. The concordance between TargetPrint and IHC/FISH was 97 % for ER, 80 % for PR, and 95 % for HER2.
    CONCLUSIONS: The implementation of multigene assays such as TargetPrint, BluePrint, and MammaPrint may improve the clinical management of breast cancer patients. High discordance between Luminal A and B substratification based on MammaPrint versus locally assessed Ki-67 or grade indicates that chemotherapy decisions should not be based on the basis of Ki-67 readout or tumor grade alone. TargetPrint serves as a second opinion for those local pathology settings where high-quality standardization is harder to maintain.

    PMID: 22965266 [PubMed - in process]

Showing results 1 - 1 of 1
Page size:
1